Almirall + Mercachem = Looking for new cytokine blockers
Published on 03/05/2017
Almirall S.A. and Mercachem have entered into an exclusive discovery collaboration focusing on the development of oral cytokine blockers for the treatment of inflammatory skin diseases.
Almirall + Nuevolution = Fighting together inflammatory skin diseases
Published on 20/03/2017
Almirall S.A. and Nuevolution A/S have entered into a global strategic collaboration focusing on the development and commercialization of Nuevolution's novel RORγt inverse agonist (inhibitor) program for treatment of inflammatory...